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Abstract: Among the gynecological malignancies, ovarian cancer is the leading cause of 
mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated 
with chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of 
first-line chemotherapy for patients with advanced ovarian cancer. Platinum-resistant ovarian 
cancer can be treated with cytotoxic chemotherapeutics such as paclitaxel, topotecan, PEGylated 
liposomal doxorubicin, or gemcitabine, but many patients eventually relapse on treatment. 
Targeted therapies based on agents specifically directed to overexpressed receptors, or to selected 
molecular targets, may be the future of clinical treatment. In this regard, overexpression of folate 
receptor-α on the surface of almost all epithelial ovarian cancers makes this receptor an excellent 
“tumor-associated antigen”. With appropriate use of spacers/linkers, folate-targeted drugs can 
be distributed within the body, where they preferentially bind to ovarian cancer cells and are 
released inside their target cells. Here they can exert their desired cytotoxic function. Based on 
this strategy, 12 years after it was first described, a folate-targeted vinblastine derivative has 
now reached Phase III clinical trials in ovarian cancer. This review examines the importance of 
folate targeting, the state of the art of a vinblastine folate-targeted agent (vintafolide) for treating 
platinum-resistant ovarian cancer, and its diagnostic companion (etarfolatide) as a prognostic 
agent. Etarfolatide is a valuable noninvasive diagnostic imaging agent with which to select 
ovarian cancer patient populations that may benefit from this specific targeted therapy.
Keywords: vintafolide, etarfolatide, platinum-resistant ovarian cancer, targeted therapy, 
 biomarkers, folate receptor
Introduction to ovarian cancer
Ovarian carcinoma is the most lethal gynecological cancer worldwide.1 The World 
Health Organization GLOBOCAN database reported a worldwide incidence of around 
200,000 cases of ovarian cancer in 2008, with a 5-year survival rate of 30%–92% 
depending on the disease spread at diagnosis. A variety of factors influence the 
risk of developing ovarian cancer (Table 1). A positive family history of ovarian or 
breast cancers is the most important factor, and nulliparity is also associated with an 
increased risk of ovarian cancer.2 Evidence concerning the effect of hormone replace-
ment therapy on the risk of developing ovarian cancer has to date been conflicting, 
although a meta-analysis has associated use of hormone replacement therapy with an 
increased risk of ovarian carcinoma.3 Other factors suggested to be associated with 
an increased risk of epithelial ovarian carcinoma, but for which the evidence is less 
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robust, include infertility,4 pelvic inflammatory disease,5 
polycystic ovaries,6 obesity,7 and animal fat consumption.8,9 
Conversely, oral contraceptive use, pregnancy, and lactation 
are associated with a reduced risk.10
About 90% of ovarian tumors are epithelial in origin, 
while the remainder comprises germ or stromal tumors. 
The World Health Organization classification describes 
three major types of epithelial adenocarcinoma, ie, serous, 
mucinous, and endometrioid. There is some evidence that the 
prognosis for women with a diagnosis of mucinous epithelial 
ovarian cancer is worse than for those with a diagnosis of 
serous histology, and the prognosis of patients with clear-cell 
histology is unlikely to be better.11,12 Treatment of ovarian 
cancer is based on surgery integrated with chemotherapy.13 
Chemotherapy plays a major role both in adjuvant treat-
ment and in the care of patients with advanced disease. 
Platinum-based drugs (cisplatin and carboplatin) are the core 
of first-line chemotherapeutics for patients with advanced 
ovarian cancer.14 Several drugs have been combined with 
cisplatin or carboplatin in an attempt to improve survival, 
and large clinical trials have confirmed the benefits of add-
ing paclitaxel to first-line chemotherapy for woman with 
advanced ovarian cancer;15 however, ovarian cancer continues 
to be characterized by stagnant mortality statistics.
A clear difference has been found between serous and 
nonserous carcinomas in terms of folate receptor (FR) expres-
sion, in particular that of overexpression of the FRα isoform 
on the surface of almost all epithelial ovarian cancers, making 
it an excellent “tumor-associated antigen” for tackling one of 
the most important challenges in ovarian cancer treatment, 
ie, platinum-resistant disease.16 For a recent review of cur-
rent approaches to treating platinum-resistant ovarian cancer, 
see Leamon et al.17 This review examines targeted treatment 
of FRα in women with platinum-resistant ovarian cancer, 
focusing especially on vintafolide and etarfolatide. The 
term “platinum-resistant” is now used to describe patients 
whose disease recurrence is documented within 6 months of 
platinum-based therapy;18,19 unfortunately these patients have 
a poor prognosis, and thus novel compounds and approaches, 
including new treatment options that are more selective and 
more individualized in their approach are welcome.
Personalized medicine in oncology
As defined by the USA President’s Council on Advisors on 
Science and Technology, 
“Personalized Medicine refers to the tailoring of medical 
treatment to the individual characteristics of each patient … 
to classify individuals into subpopulations that differ in their 
susceptibility to a particular disease or their response to a 
specific treatment. Preventive or therapeutic interventions 
can then be concentrated on those who will benefit, sparing 
expense and side effects for those who will not.”20 
The concept of personalized medicine is closely related to 
the concept of targeted therapy, given that the possibility to 
treat each patient in the best way is linked to the possibility 
of recognizing a specific molecular target to drive selective 
drugs. Undoubtedly, oncology is a promising field for this 
kind of approach, because molecular targets that are specific 
for a particular tumor can frequently be identified. The objec-
tive of personalized cancer treatment is to select the ideal 
therapy for an individual cancer patient, based on knowledge 
of that patient’s tumor characteristics and/or genetics. The 
first example of application of targeted therapy was ima-
tinib, a tyrosine kinase inhibitor that can improve survival in 
patients with chronic myelogenous leukemia and who carry a 
particular translocation in their leukemic white blood cells.21 
Another example of an application of targeted therapy con-
cerns colorectal cancer, for which drugs targeting epidermal 
growth factor receptor, such as cetuximab or panitumumab, 
or those targeting vascular endothelial growth factor, such as 
bevacizumab, have entered routine clinical use.22–24 The FR 
is thus a valuable therapeutic target in ovarian cancer since 
it is highly expressed on a variety of cancers, whereas it is 
largely absent from normal tissue. The identification of FRα 
as a molecular target may lead to the development of drugs, 
specifically targeted to ovarian cancer cells.
Introduction to the folate receptor
FRs are cysteine-rich cell surface glycoproteins that bind 
folate with high affinity. Three FR isoforms have been iden-
tified to date, ie, FRα, FRβ, and FRγ. In 2000, Spiegelstein 
et al, through genome database mining, identified a fourth 
isoform, FRδ, but neither its tissue expression nor its func-
tionality as a folate binder has been clearly established.25 
These receptors actually comprise a family of proteins, 
since they share highly conserved sequences and are all 
Table 1 Risk factors for developing ovarian cancer
Increased risk Decreased risk
Age Oral contraceptive use
High-fat diet Pregnancy
inherited predisposition Lactation
Nulliparity
Ovulation
Pelvic inflammatory disease
Polycystic ovarian disease
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encoded by the folate receptor multigene family, which is 
localized on chromosome 11q13.3–q14.1.26
FRα and FRβ are the most studied isoforms; they are 
membrane-anchored receptors and mediate internalization of 
receptor-bound folate compounds and folate conjugates.27–30 
FRγ is primarily a secretory protein, in that it lacks an efficient 
signal for glycosylphosphatidylinositol (GPI) modification.31 
FRα and FRβ, in particular, are colocalized in lipid rafts, ie, 
membrane microdomains that function as platforms able to 
recycle GPI-anchored proteins.32 All FR isoforms bind folic 
acid with high affinity (Kd ,1 nM). In contrast, FRα and FRβ 
display different affinities towards reduced folate isoenzymes; 
for example, FRα has 50 times greater affinity than FRβ for 
N5-methyltetrahydrofolate. This difference is correlated with the 
different amino acid composition of the two receptors, namely 
Leu-49 in FRβ, and Ala-49, Val-104, and Glu-166 in FRα.33,34
In 1986, Elwood et al identified a soluble high-affinity 
folate-binding protein in the KB human nasopharyngeal cell 
line,35 which was also isolated from extracellular fluids such 
as human milk36 and human placenta.37 It has been shown that 
soluble high-affinity folate-binding protein may originate from 
FRα or from FRβ, as well as from FRγ.34 That soluble high-
affinity folate-binding protein can originate from FRα was dem-
onstrated in KB and placenta cells, where it was derived either 
by proteolysis mediated via an Mg2+-dependent protease or by 
phospholipase cleavage of the GPI anchor.38,39 FRβ is processed 
intracellularly via two independent pathways; one results in GPI 
anchor addition and the other results in its secretion.40
Specific role of FR in ovarian cancer
The significance of this receptor as a tumor marker was 
discovered in 1991 when, through amino acid sequence 
analysis, a protein enriched on the surface of a human ovar-
ian carcinoma cell line was shown to be the FR.41 The FR 
was later shown to be expressed on the majority of nonmu-
cinous ovarian carcinomas, and subsequent analyses have 
revealed more marked upregulation of the FRα isoform 
than of the other isoforms in ovarian carcinoma.42,43 It has 
been suggested that FRα might confer a growth advantage 
on the tumor by modulating folate uptake from serum, which 
in turn might facilitate rapid cellular growth and division. 
Alternatively, it has been suggested that FRα might affect 
cell proliferation via cell signaling pathways, similarly to 
other cellular membrane proteins with a GPI anchor.44,45 It 
also appears possible that FRα levels may be elevated during 
the early stages of carcinogenesis, when they would increase 
folate uptake and stimulate cells to repair DNA damage in 
transcription factors or in other proteins.46 The inability of 
these cells to repair these proteins coding DNA might lead 
to continued FRα expression, which could eventually sup-
port the transition to a cellular environment favoring tumor 
progression and increasing the tumor folate requirements 
for rapid growth.47
Comparatively little attention has been paid to FRα 
levels and patient survival in ovarian cancer; in one such 
study, expression of FRα protein was found to be associated 
with tumor progression.48 In another study it was associated 
with high-grade ovarian cancers, platinum therapy resistance, 
and poor prognosis,49 suggesting that metabolic changes 
related to its upregulation may occur early in carcinogenesis; 
the study authors offered some hypotheses to explain their 
findings, including that FRα may increase folate uptake, 
which could stimulate cells to repair DNA damage caused 
by platinum, or that FRα involvement in signal transduction 
could help cells progress through the cell-cycle phases faster 
than cells with lower levels of FRα, or again that FRα might 
predispose cells to overcome drug-induced injury, as observed 
for genes involved in cellular signaling or apoptosis.50,51
A recent study16 confirmed an FRα expression rate of 
roughly 82% in patients with serous ovarian cancer, although 
expression was marked in a small proportion of these cases. 
Further, the study authors showed that chemotherapy does 
not significantly alter FRα expression in vital residual tumor 
tissue, suggesting an important role for FRα as a target for 
diagnostic agents and drugs. The limited tissue-specific 
expression of the FR isoforms enables FRα to be exploited 
for the selective delivery of cytotoxic agents into malignant 
cells, with reduced toxic side effects in nontarget tissues.
For these reasons, FRα is an appropriate target for cancer 
immunotherapy with monoclonal antibody-based reagents. 
Specific monoclonal antibodies (bearing radioisotopes) may 
be used for imaging and/or therapeutic purposes (used alone, 
as bispecific monoclonal antibodies, or after conjugation with 
toxins, drugs, radionuclides, or cytokines). Several anti-FRα 
antibodies have been developed, the most interesting being 
the murine monoclonal antibodies MOv18, MOv19, and 
LK26. These recognize two noncompeting epitopes of FRα, 
and have been developed by Miotti et al42 and Garin-Chesa 
et al.52 Guided selection of MOv18 or MOv19 resulted in an 
optimization process that led to a chemical dimer, AFRA-
DFM5.3, now in advanced preclinical evaluation.53 An opti-
mized process of humanization of LK26 led to farletuzumab 
(MORab-003; Morphotek Inc., Exton, PA, USA). In this case, 
the cytotoxicity of the monoclonal antibody is mediated via 
complement-dependent cytotoxicity and antibody-dependent 
cell-mediated cytotoxicity. Promising initial findings led to 
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advanced clinical trials (NCT01218516) in platinum- sensitive 
patients who experienced first relapse to determine the effi-
cacy of farletuzumab as monotherapy and in combination 
with carboplatin/taxane.54,55 Meanwhile, Phase II trials of far-
letuzumab as a first-line agent in combination with traditional 
platinum-containing chemotherapies in lung adenocarcinoma 
are ongoing (NCT01218516).56 Recently, a Phase III trial 
(FAR-122, NCT00738699) of farletuzumab in combination 
with paclitaxel in advanced platinum-resistant ovarian cancer 
has been discontinued because of its limited survival benefit 
for patients.57 Additionally, some immune-mediated events 
were observed. Furthermore, Morphotek Inc has announced 
that it is actively developing a companion diagnostic assay 
to identify patients with high FRα expression because these 
patients may receive more benefit from farletuzumab therapy 
than those with low FR expression.58
The rationale underlying FRα-targeted drug delivery lies 
in the substrate specificity of folic acid versus FRα. In this 
type of approach, folate can be linked to various therapeutic 
agents, namely low-molecular-weight chemotherapeutic 
agents, liposomes with entrapped drugs, antisense oligo-
nucleotides, and immunotherapeutic agents, that can then 
target cancer cells that overexpress FR.59 This is possible 
because folate is amenable to chemical conjugation with other 
molecules through its γ-carboxyl group, without decreasing 
its binding affinity to the FR.60 In this connection, Leamon 
and Low have introduced a novel and personalized approach 
to identifying patients who are most likely to benefit from 
FR-targeted therapy (Figure 1).59 This strategy has led to 
the development of several small-molecule drug conjugates 
to target cells that overexpress all the FR isoforms.61 One 
of the most promising and the one studied in most depth is 
vintafolide (originally known as EC145), which combines 
a water-soluble derivative of folic acid (pteroic acid) and 
desacetylvinblastine hydrazide, a potent vinca alkaloid 
(Figure 2).62 The two molecules are connected in a regio-
selective manner via a hydrophilic peptide spacer and a 
self-immolative group based on disulfides as the cleavable 
linkage. Desacetylvinblastine hydrazide is prepared from 
vinblastine-free base by reaction with anhydrous hydrazine, 
whereas the targeting and spacer components are prepared 
by assembly, using standard fluorenylmethyloxycarbonyl-
based solid-phase peptide synthesis. The second step involves 
inserting the disulfide cleavable linkage on desacetylvinblas-
tine hydrazide by reaction with the heterobifunctional reagent 
(2-[benzotriazole-1-yl-(oxycarbonyloxy)-ethyldisulfanyl]-
pyridine). The final reaction comprises a mild thiol-disulfide 
exchange reaction between the components.
The companion imaging agent has also been developed, 
and is known as etarfolatide (EC20), which contains a 99mTc-
based imaging group61 (Figure 2). Through an efficient 
solid-phase synthetic procedure, a small-molecular-weight 
peptide derivative of folate (Cys-Asp-Dap-D-Glu-Pte) was 
produced. A D-Glu enantiomer residue was incorporated 
a.   Endocytosis of the the SMDC
      after folate receptor binding
b.   The SMDC is cleaved inside
      the endosome
c.   Drug can exerts its activity
d.   Folate receptor recycles
      on cell membrane
Drug
Linker
(cleavable bond) Folate(targeting ligand)
Hydrophilic
spacer
Folate receptor positive
ovarian cancer cell
Ovarian cancer
cell death
Folate receptor α
(folate high affinity)
a
b
c
d
Small molecule drug conjugates
(SMDC)
Figure 1 Mechanism of action of a folate-targeted drug conjugate.
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into the molecule for the purpose of providing additional 
metabolic protection against tissue-resident hydrolases, 
without altering the ability of folic acid to bind to the high-
affinity FR.63
Efficacy and safety of vintafolide  
and etarfolatide
In preliminary work, vintafolide was fully characterized 
using a KB human nasopharyngeal cancer cell line that over-
expresses FR. KB cell lines treated with a short incubation 
pulse (1–2 hours) of vintafolide showed high cytotoxicity 
values (around 9 nM, versus 2 nM for free vinblastine). The 
specificity of vintafolide was demonstrated by two methods, 
ie, using a free folic acid excess in the KB cell line and testing 
the compounds in the 4T1 FR-negative cell line, in which 
activity was either completely blocked or not observed.
Vintafolide has been tested in a number of different 
in vivo models, including M109 mouse lung adenocarcinoma, 
a KB tumor xenograft model, and aggressive FR-positive 
J6456 lymphoma. In all these cases, vintafolide exerted a 
notable antitumor effect. The KB tumor model was also used 
to evaluate the effect of dosage and treatment schedule on 
therapeutic efficacy, with different schedules evaluated using 
a fixed total quantity of 12 µmol/kg. The most efficacious 
(100% cure rate) was found to be that entailing frequent 
administration of lower doses of vintafolide, ie, once daily for 
5 days. Furthermore, etarfolatide, the radiodiagnostic imag-
ing agent, showed that uptake by the liver (nontargeted organ) 
increased and was proportional to the dose administered. 
Increased uptake in the liver and a concomitant drop in 
uptake by the tumor could explain the observed reduction 
in antitumor effect of vintafolide when administered using 
the lower-frequency, higher-dose regimens.
Determination of the toxicity of novel anticancer agents, 
especially those bearing very potent molecules such as 
desacetylvinblastine hydrazide, is a difficult challenge. In 
a study in which KB or M109 tumors were grown in mouse 
models, aside from minimal-to-moderate weight loss during 
therapy, no other gross toxicity was observed after admin-
istration of 5 µg/kg or 10 µg/kg once daily for 5 days. With 
the exception of the liver, all other tissues appeared to be 
normal. An important finding was the lack of renal toxic-
ity, despite the fact that mouse kidneys express very high 
levels of FR.64
The first clinical pharmacokinetic evaluation was reported 
in a single-center, dose-escalation, open-label, Phase I 
clinical trial (EC-FV-01, NCT00308269) completed in 2007, 
which involved 32 patients with refractory or metastatic solid 
tumors (six affected by ovarian cancer).65 Vintafolide was 
administered either as an intravenous injection on days 1, 3, 
5 (week 1) and days 15, 17, 19 (week 3) of a 4-week cycle 
at doses of 1.2, 2.5 and 4.0 mg (in three, ten, three patients, 
respectively), or as a one-hour infusion administered on the 
same schedule at doses of 2.5 mg and 3 mg (ten and six 
patients, respectively).
The pharmacokinetic profile is accurately described 
by a two-compartment model, and is characterized 
by rapid distribution and elimination (half-life 6 and 
26 minutes, respectively). The area under the concentration-
time curve values for administration of 2.5 mg as an 
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intravenous bolus or as a one-hour infusion were equivalent 
(42–40 hours*ng/mL), while the time to peak concentration 
values were 129 ng/mL and 42 ng/mL, respectively. The 
same study also included a population analysis, in which 
vintafolide showed a clearance of 56.1 L/hour, with an inter-
individual variability of 48% and an interoccasion variability 
of 8%. Significant covariance of clearance with body surface 
area was found, although other covariates not tested in the 
study may account for a larger proportion of the interindi-
vidual variability. The volume of distribution at steady-state 
was 26 L.66 From the pharmacokinetic and clinically relevant 
toxicity evaluations performed in this trial, a well tolerated 
intravenous bolus dose of 2.5 mg was recommended as the 
dose to be used in the Phase II trial.
Regarding diagnostics for recurrent ovarian carcinoma, 
111In-DTPA-folate was the first FR-targeted low-molecular-
weight agent to enter clinical trials.67 Due to the relatively 
long half-life and high cost of 111In, a 99mTc-based imaging 
agent (half-life 6 hours) was greatly preferable; etarfolatide 
was tested and radiopharmaceutical analysis showed it to 
have a time-dependent and concentration-dependent asso-
ciation with FR-positive cells. It appeared to accumulate 
preferentially within FR-positive tumors, and to do so in large 
amounts. Furthermore, its rapid pharmacokinetics (cleared 
from the blood with a half-life of 4 minutes) improves its 
quality for use as a diagnostic imaging agent.63
An in vivo pilot study was performed to determine the 
percentages of various solid tumors that accumulate etarfo-
latide, and to correlate its uptake with immunohistochemistry 
analysis of FR expression in available biopsied tumor tissue 
from 154 patients.68 As determined by immunohistochem-
istry staining for the FRα isoform, 67% of these patients 
had FR-positive tumors. Overall, the etarfolatide evaluation 
corresponded to the immunohistochemistry staining result 
in 61% of patients. Agreement between etarfolatide-positive 
results and FR-positive results was 72%, whereas agreement 
between etarfolatide-negative results and FR-negative results 
was 38%. This relatively poor agreement between imaging 
and immunohistochemistry results may be explained in 
part by the fact that the study was not designed as a lesion-
to-lesion comparison between the two methods. The study 
authors suggest that the discrepant results for the two methods 
may reflect a difference in FR status of the primary neoplasm 
versus metastatic disease after excision of the primary tumor, 
or a difference in FR expression between metastatic lesions 
in the same patient.68 Administration of etarfolatide was safe, 
and the investigators considered that none of the 17 serious 
adverse events were “related” to administration of the imag-
ing agent. Rather than diagnosis, the primary purpose of 
etarfolatide administration is currently as a companion agent 
to enable preselection of patients whose tumors are highly 
FR-positive, and who thus constitute the best candidates for 
FR-targeted therapy. Etarfolatide has been a component of 
more than 16 clinical trials in over 500 patients with ovar-
ian, endometrial, renal, pituitary, and pulmonary cancers, 
and has been shown to be valuable for predicting response 
to FR-targeted chemotherapy.
Clinical studies to evaluate the safety and efficacy of 
vintafolide started in 2007 with a nonrandomized Phase II 
clinical trial (NCT00507741, EC-FV-02)69 in patients with 
advanced ovarian, fallopian tube, or primary peritoneal 
carcinoma, after identification of FR expression using etar-
folatide (n=47, median age 61 years). The trial, completed at 
the end of 2012, examined two different doses of vintafolide, 
administered three times a week on weeks 1 and 3 (4-week 
cycle). The primary endpoint was the percentage of patients 
deriving clinical benefit. The disease control rate (complete 
response + partial response + stable disease) at 8 weeks in 
patients receiving vintafolide as third-line or fourth-line 
intravenous therapy was 75%, compared (historically) with 
a rate of 47% in women receiving second-line or third-line 
PEGylated liposomal doxorubicin (hereafter PLD).19,70 There 
were also three partial responses.
From this study, it appeared that vintafolide was very 
well tolerated, with minimal toxicity. Fatigue was the most 
common grade 3 toxicity, occurring in 8.2% of patients.71 In 
this initial trial, the patients were not preselected by expres-
sion of FR; however, the lesional uptake of etarfolatide was 
assessed retrospectively to determine whether the level of 
radioactive positivity in tumors correlated with vintafolide 
response rates.72 Evaluable tumor lesions (n=145) were 
classified according to three levels of etarfolatide uptake 
(ie, ++, +, -). The probability of a response was greater with 
+ than with – lesions (P=0.0022). The disease control rate 
was 57% (++), 36% (+), and 33% (-) for patients with differ-
ently responsive lesions, whereas the disease control rate was 
42.2% for all lesions regardless of response status. The overall 
response rate was 14% for patients with the most strongly 
positive lesions, and 0% for patients with less positive or 
negative lesions. Among a subgroup of patients who had 
failed fewer than three previous treatments, a disease control 
rate of 86% was observed for patients with high etarfolatide 
uptake (++), compared with 50% (+) and 0% for those with 
less reactive lesions (-). The group of patients with highly 
reactive lesions had a median overall survival of 63.4 weeks, 
compared with 23.1 weeks using pooled data from all other 
patients; in addition, a trend towards longer survival was 
observed in the first group of patients (P=0.071).72
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An international, randomized Phase II study (EC-FV-04, 
NCT00722592, Platinum Resistant Ovarian Cancer Evalu-
ation of Doxil and EC145 Combination Therapy [PREC-
EDENT]) completed in 2013 compared coadministration 
of vintafolide and PLD with a liposome formulation alone 
in women with platinum-resistant ovarian cancer (n=149).73 
Patients were randomized to receive vintafolide (2.5 mg on 
days 1, 3 and 5 and days 15, 17 and 19 of each 4-week cycle) 
plus PLD (50 mg/m2 intravenously, on day 1 of each 4-week 
cycle) or PLD alone (at the same dosage/schedule) until 
disease progression or death. No statistically significant dif-
ference between the study arms was found with regard to total 
adverse events. An interim analysis (conducted after the 46th 
event, of a planned study total of 95 progressions or deaths) 
indicated that median progression-free survival was 20 weeks 
for women receiving vintafolide plus PLD (P=0.014), com-
pared with 10.8 weeks in the PLD alone group.74 Vintafolide 
plus PLD was the first combination to show a statistically 
significant increase in progression-free survival (versus 
controls) for women with platinum-resistant ovarian cancer. 
Another combination, ie, trabectedin/PLD, appeared only to 
benefit the partially platinum-sensitive subgroup. The full 
evaluation of this study has very recently been published.75 To 
evaluate the association between progression-free survival, 
hazard ratio, and level of FR positivity, a threshold analysis 
was conducted based on etarfolatide scan results (Table 2). 
Benefit was observed in patients with FR positive disease 
(10% to 90%, FR 10%–90%), and in patients with 100% 
of lesions positive for FR (FR 100%); it was greatest in 
FR 100% patients, with a median progression-free survival 
of 22 weeks compared with 6.6 weeks for PLD alone. Of 
note, FR 100% patients in the PLD arm seemed to have a 
poorer prognosis, with the shortest median progression-free 
survival of any group (1.5 months); this is consistent with 
reports regarding the correlation between FR expression 
and poor outcome.48 Based on these promising results, 
a randomized, double-blind, placebo-controlled Phase III 
study (NCT01170650, Study for Women With Platinum 
Resistant Ovarian Cancer Evaluating EC145 in Combi-
nation With Doxil® [PROCEED]) is currently recruiting 
patients with platinum-resistant ovarian cancer.76 At baseline, 
patients undergo etarfolatide imaging to identify FR-positive 
lesions; they are then randomized to vintafolide with or 
without PLD. PLD 50 mg/m2 is administered on day 1 of a 
4-week cycle and treatment continues until the maximum 
allowable cumulative dose (550 mg/m2) is reached, or until 
disease progression or intolerable toxicity. Vintafolide 2.5 mg 
or placebo is administered on days 1, 3, 5, 15, 17, and 19 of a 
4-week cycle, and treatment can continue for up to 20 cycles, 
or until unacceptable toxicity or disease progression. The 
primary objective is to assess progression-free survival based 
on investigator assessment (Response Evaluation Criteria In 
Solid Tumors version 1.1) in FR-positive patients.77 Secondary 
objectives include investigation of overall survival, safety/
tolerability, overall response rate, and disease control rate.78 
Table 3 summarizes the main characteristics of the clinical 
trials described here.
The FR-targeted approach is currently being investigated 
in breast cancer. An open-label, randomized Phase IIa trial is 
underway to evaluate the safety and efficacy of vintafolide 
and the vintafolide plus paclitaxel combination in subjects 
with advanced triple-negative breast cancer; etarfolatide was 
used for subject selection (NCT01953536).79 A Phase I study 
of the safety of vintafolide in combination with carboplatin 
and paclitaxel in patients with FR-reactive endometrial cancer 
(NCT01688791) is ongoing.80
Adverse effects
The adverse effects of vinblastine are important, relate to 
its hematologic toxicity, and are dose-limiting; in addition, 
nausea, constipation, mucositis, and stomatitis are common. 
Neurotoxicity occurs less frequently than with vincristine, 
and is characterized by peripheral neuropathy.81 Vinblastine 
is a vesicant, and extravasation precautions must be applied. 
Table 2 Threshold analysis of progression-free survival in patients with platinum-resistant ovarian cancer based on etarfolatide scan
Status Vintafolide + PLD arm PLD alone arm
No. of  
Patients
Total 
Events
Median PFS 
(months)
No. of  
Patients
Total 
Events
Median PFS 
(months)
HR 95% CI P-value
miTT 100 62 5.0 49 33 2.7 0.626 0.409–0.959 0.031
FR 10%–100% 48 30 5.7 26 19 1.7 0.547 0.304–0.983 0.041
FR 100% 23 15 5.5 15 13 1.5 0.381 0.172–0.845 0.013
FR 10% –90% 25 15 5.7 11 6 7.0 0.873 0.334–2.277 0.790
FR 0% 13 8 3.8 7 2 5.4 1.806 0.369–8.833 0.468
Note: Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved. Naumann Rw, Coleman RL, Burger RA, et al. PReCeDeNT: a 
randomized Phase ii trial comparing vintafolide (eC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant 
ovarian cancer. J Clin Oncol. 2013;31(35):4400–4406.74
Abbreviations: FR, folate receptor; HR, hazard ratio; CI, confidence interval; mITT, intent-to-treat population of patients with measurable disease; PFS, progression-free 
survival; PLD, PeGylated liposomal doxorubicin. 
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vintafolide and etarfolatide in ovarian cancer
When evaluating folate-directed vinblastine conjugates, care 
must be taken to guard against any potential nephrotoxicity 
due to the high expression of FR in the kidneys. During a dose-
escalating clinical trial in 32 patients, vintafolide was generally 
well tolerated. Decreased gastrointestinal motility (constipa-
tion) and peripheral sensory neuropathy were reported as 
adverse events. Twenty-six of the 32 patients reported at least 
one drug-related adverse effect. Constipation appeared to be 
dose-dependent, predictors were found to be clearance and area 
under the concentration-time curve.65 Dose-limiting toxicity 
at 4 mg included reversible ileus and neuropathy. The same 
adverse effects (all grades/grade $3) were observed during the 
EC-FV-03 study in the 22 patients for whom full toxicity data 
were available, ie, fatigue (8/1), constipation (6/0), anorexia 
(5/1), weight loss (3/0), and dyspepsia (2/0).82
The safety data collected during the NCT00722592 
(PRECEDENT) trial showed that there were no cumulative 
treatment-emergent adverse events except for palmar–plantar 
erythrodysesthesia syndrome, which is frequently related to 
PLD. The frequencies of leukopenia, neutropenia, abdominal 
pain, and peripheral sensory neuropathy were significantly 
higher in the vintafolide plus PLD arm than in the PLD arm. 
No drug-related mortality or statistically significant differ-
ence in incidence of serious drug-related events was observed 
between treatment arms, and all adverse events occurred in 
fewer than 5% of patients, with the exception of small bowel 
obstruction (vintafolide plus PLD arm, 8.4%; PLD arm, 
12%).75 However, despite clinical efforts to minimize the 
adverse effects of vintafolide, peripheral neuropathy remains 
an important toxicity. A possible strategy to avoid peripheral 
neurotoxicity might be to seek a balance between the potential 
therapeutic efficacy of high doses and the potential of such 
doses to cause painful peripheral neuropathy.
Place in therapy
Epithelial ovarian cancer is the most lethal gynecological 
malignancy among women worldwide. Most women present 
with advanced disease, and despite excellent responses to 
initial surgery and chemotherapy, 5-year survival statistics 
remain poor. Among several new therapeutic approaches 
for ovarian cancer, FR-targeted agents show significant 
promise.58,83 The fact that FRα is overexpressed in ovarian and 
other cancer cells, while its expression is limited in normal 
tissues, accentuates its potential as a diagnostic and thera-
peutic target.54,83 Strategies of this sort might allow treatment 
to be selected based on a tumor’s molecular characteristics, 
advancing therapy from empirical cytotoxic therapies to more 
individualized ones.
Vintafolide, administered in combination with PLD, is the 
first combination to lead to a statistically significant increase 
in progression-free survival for women with platinum-
 resistant ovarian cancer. Our knowledge of FR has very 
recently been enhanced through crystallographic models, 
which reveal representative stages of endocytic trafficking 
and conformation changes occurring in FRs.84 These data 
would appear to provide a platform from which to rationally 
design drugs as lead compounds with greater selectivity, 
together with excellent diagnostic agents, which together 
can greatly reduce nonspecific effects; this may lead to the 
development of more potent but safer therapeutic agents. 
However, as may be seen in the case of vintafolide, the time 
lag between design and clinical use is still several years.85
In the future, prescreening a patient’s FR status using 
etarfolatide may also become a companion diagnostic tool 
for other FR-targeted agents. Etarfolatide might be used to 
select FR-positive patients and, in combination with fluores-
cent folate-targeted compounds, could allow more precise 
removal of tumor tissue.86
In conclusion, vintafolide is showing itself to be an impor-
tant tool in the treatment of ovarian cancer, particularly for the 
patient population with platinum-resistant ovarian cancer, for 
whom the prognosis is very poor. These promising new pos-
sibilities, if confirmed, will mark the achievement of a new goal 
in oncology; by utilizing targeted therapy, there is the possibil-
ity of targeting therapy to the area where a specific molecular 
target is present, in this case a marker of ovarian cancer.87 The 
FR-targeting approach is also steadily improving, delivering 
more than one type of cytotoxic agent to tumors simultaneously. 
In this next generation of conjugates, folate is tethered to two 
different drug molecules, eg, mitomycin C and vinca alkaloids, 
with distinct biological mechanisms of action.88
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